**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 2641**

**Columns: REVIEW**

Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases

**Abu-Wasel B *et al*.** Polycystic Liver Disease

Bassam Abu-Wasel, Caolan Walsh, Valerie Keough, Michele Molinari

**Bassam Abu-Wasel,** **Caolan Walsh, Michele Molinari,** Department of Surgery, Dalhousie University, Halifax, Nova Scotia B3H 2Y9, Canada

**Valerie Keough,** Department of Radiolgoy, Dalhousie University, Halifax, Nova Scotia B3H 2Y9, Canada

**Michele Molinari,** Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia B3H 2Y9, Canada

**Author contributions:** Abu-Wasel B performed the review of the literature, wrote the paper and created the diagrams used in this review; Walsh C performed the review of the literature and edited the final draft; Keough V performed the selection of cross sectional studies, reviewed the literature on radiological classification of polycystic liver disease and edited the final draft; Molinari M ideated the paper, performed the review of the literature, edited the paper and selected some of the relevant radiological images.

**Correspondence to: Michele Molinari, MD, MSc, Associate Professor,** Department of Surgery and Community Health and Epidemiology, Dalhousie University, 1276 South Park Street, Room 6-302 Victoria Building, Halifax, Nova Scotia B3H 2Y9, Canada. michele.molinari@cdha.nshealth.ca

**Telephone:** +1-902-4737624 **Fax:** +1-902-4737639

**Received:** March 5, 2013 **Revised:** May 21, 2013

**Accepted:** July 9, 2013

**Published online:**

**Abstract**

Polycystic liver diseases (PLD) represent a group of genetic disorders in which cysts occur in the liver (autosomal dominant polycystic liver disease) or in combination with cysts in the kidneys (autosomal dominant polycystic kidney disease). Regardless of the genetic mutations, the natural history of these disorders is alike. The natural history of PLD is characterized by a continuous increase in the volume and the number of cysts. Both genders are affected; however, women have a higher prevalence. Most patients with PLD are asymptomatic and can be managed conservatively. Severe symptoms can affect 20% of patients who develop massive hepatomegaly with compression of the surrounding organs. Rrarely, patients with PLD suffer from acute complications caused by the tortion of hepatic cysts, intraluminal cystic hemorrhage and infections. The most common methods for the diagnosis of PLD are cross sectional imaging studies. Abdominal ultrasound (US) and computerized tomography (CT) are the two most frequently used investigations. MRI is more sensitive and specific, and it is a valuable test for patients with intravenous contrast allergies or renal dysfunction. Different treatment modalities are available to physicians caring for these patients. Medical treatment has been ineffective. Percutaneous sclerotherapy, trans-arterial embolization, cyst fenestration, hepatic resection and liver transplantation are indicated to specific groups of patients and have to be tailored according to the extent of disease. This review outlines the current knowledge of the pathophysiology, clinical course, diagnosis and treatment strategies of PCLD.

© 2013 Baishideng. All rights reserved.

**Key words:** Polycistic liver disease; Hepatic; Epidemiolgy; Classification; Therapy; Genetic

**Core tip:** The management of patients with symptomatic polycystic liver disease is challenging. Among several treatments options, the most common interventions are: percutaneous cyst aspiration, fenestration, hepatic resection and liver transplantation. There is no consensus on the best treatment options and the optimal timing for interventions in symptomatic patients. In vision of these limitations, we reviewed the most recent literature and present a comprehensive article on this topic.

Abu-Wasel B, Walsh C, Keough V, Molinari M. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

**Available from: URL:**

**DOI:**

**INTRODUCTION**
The association between polycystic liver disease (PLD) and autosomal dominant polycystic kidney disease (ADPKD) was described for the fist time by Bristowe in 1856[1, 2]. Initially, it was thought that PLD could develop only in the context of ADPKD[3]. The notion that isolated PLD might be a separate condition was proposed in the 1950’s[4]. In 2003, a linkage analysis of eight Finnish families confirmed that PLD is genetically distinct from ADPKD[5]. Asymptomatic patients usually do not require any intervention[6]. In some patients, massive hepatomegaly can cause pain or compression of the adjacent gastrointestinal organs, vasculature, and diaphragm. This can have a significant effect on patients’ quality of life and performance status[6, 7]. For these patients, the main aim is to reduce their symptoms by decreasing the liver volume[8-10]. Current surgical options include open or laparoscopic cyst fenestration with or without hepatic resection and orthotopic liver transplantation (OLT). Significant advances in surgical techniques have improved the outcomes of PLD patients. However, the selection of the appropriate approach remains a clinical challenge, and there is no consensus on the optimal timing and what represents the best therapeutic modality.

**INCIDENCE AND GENETICS**

ADPKD affects up to 0.2% of the general population[11]. On the other hand, isolated PCLD has prevalence of less than 0.01%[12]. Both ADPKD and PLD are autosomal dominant and 75%-90% of patients with ADPKD have associated PLD[13]. In humans, PLD has been linked to mutations of four genes. Two genes (PKD1, locus 16p13.3, encoding polycystin-1 and PKD2, locus 4q21, and encoding polycystin-2) are predominantly associated with renal disease and less frequently with PLD. PKD1 mutations are more common and account for 85–90% of the cases, whereas mutations in PKD2 affect approximately 10–15% of patients[11]. The remaining two mutations (PRKCSH, locus 19p13.2, encoding the protein kinase C substrate 80K-H or hepatocystin and SEC63, locus 6q21, encoding the Sec63 protein) are linked only to the development of PLD[11]. However, these mutations explain just 25% to 40% of cases of PLD[14,15]. Comparative characteristics between ADPKD and PLD are summarized in Table 1.

**PATHOPHYSIOLOGY**
Malformation of the hepatic ductal plate and cilia of cholagyocytes is the main characteristic linked to the pathophysiology of PLD (Figure 1).

 **DUCTAL-PLATE MALFORMATION**

The ductal plate is the anatomical template for the development of the intra-hepatic bile ducts[16]. Normal bile ducts arise from the ductal plate through a complex sequence of growth and apoptosis. Complexes of disconnected intralobular bile ductules (von Meyenburg complexes) are retained because they do not undergo apoptosis in PLD[10]. As a consequence, multiple cysts arise from progressive dilatation of these abnormal ductules[17-19] that display the same epithelium and structures of functioning cholangiocytes[20, 21].

**ABNORMAL PRIMARY CILIA**

Cholangiocytes are the only ciliated cells in the liver. Cilia have mechanosensory capacity and modulate the intracellular levels of cAMP and Ca2+ when bent by the flow of bile. They also detect changes in osmolarity and composition of the bile[22-24]. Ciliary defects result in a decreased cytoplasmic level of Ca2+ and an increased cytoplasmic level of cAMP[25]. These changes are responsible for the hyperproliferation of cholangyocites and for the cystogenesis that is a consequence of the altered balance between fluid secretion and absorption in the lumen of the biliary ducts[25].

**NATURAL HISTORY AND RISK FACTORS FOR PLD**

The natural history of PLD is characterized by a continuous increase in the volume and the number of cysts[11, 26, 27]. The annual growth of affected livers is in the range of 0.9–3.2% of the initial hepatic volume[10, 28-30]. Both genders are affected; however, women have a higher prevalence. Exposure to estrogen during pregnancies, the use of oral contraceptive pills or estrogen replacement therapy seems to accelerate the progression of the disease[1, 27, 31]. Other risk factors are the severity of renal dysfunction that is dependent on the volume of the cysts in the kidneys[1]. Table 2 summarizes the known factors that influence the progression of PLD.

**CLINICAL PRESENTATION**

PCLD is asymptomatic in 80% of patients[8, 9] and is usually diagnosed incidentally. Women present with massive and symptomatic cystic liver more frequently than men[32]. For 20% of patient, symptoms are typically caused by the compression of organs surrounding the liver, bleeding or infectious complications of the cysts. Compressive symptoms include abdominal distention, early satiety that can lead to decreased oral intake and severe malnutrition, gastro-esophageal reflux, dyspnea, hepatic venous-outflow obstruction (Budd-Chiari Syndrome), inferior vena cava syndrome, portal-vein and bile-duct compression. Complications of liver cysts include infections, torsions, rupture and hemorrhage[1, 18, 33, 34] (Table 3). In asymptomatic patients, serum laboratory studies are usually normal. In the presence of symptoms, 47% of patients have elevated serum alkaline phosphatase, 70% have elevated serum levels of gamma glutamil transferase[35-38], 27% have elevated serum levels of aspartate amino transferase and 15% have elevated serum levels of total bilirubin[35, 36]. Liver synthetic function is typically preserved despite the presence of innumerable cysts[32] while 45% of patients might have elevated serum tumor marker CA 19-9 without proof of malignancy[39]. Other tumor markers such as CA-125, CEA, and alpha-fetoprotein may also be elevated but less frequently than CA19-9[40-42].

 **ASSOCIATED EXTRA-HEPATIC DISEASES**

 Intracranial arterial aneurysms can affect 6% of patients without a family history of ADPKD and up to 16% of patients with family history of ADPKD. Other common conditions are mitral-valve prolapse and colonic diverticulosis that can be detected in 25% of patients with PLD[1, 11, 43-45]. Screening for intracranial aneurysm by magnetic resonance angiography (MRA) is recommended only for patients with ADPKD, older than 30 years or for those patients with family history of hemorrhagic strokes or intracranial arterial aneurysms[46]. Screening for intracranial arterial aneurysms is also warranted in cases of a sudden severe headache, or for candidates to liver or kidney transplantation. Screening for mitral-valve prolapse is not recommended unless a cardiac murmur is ascultated during routine clinical examinations[11, 47]. Finally, patients with ADPKD may have asymptomatic cysts within other organs, such as the pancreas, spleen, ovaries, and lungs[48]. Pancreatic cysts are the most common with a reported incidence of 9% among ADPKD patients older than 30 years[49-51].

**DIAGNOSIS**
The most common methods for the diagnosis of PLD are cross sectional imaging studies. Abdominal ultrasound (US) and computerized tomography (CT) are the two most frequent investigations[52, 53]. For hepatic cysts, MRI is more sensitive and specific, and it is a valuable test for patients with intravenous contrast allergies or renal dysfunction or when other studies are unable to satisfy the diagnostic needs[54]. Hepatic cysts have radiological characteristics identical to benign developmental cysts. On US, they appear anechoic and well-circumscribed[55]. On CT and MRI, they have non-enhancing, well-circumscribed round walls with hypodense content[55]. On T2-weighted MRI and CT scans, they appear homogenously enhanced spherical lesions[55] (Figure 2B, C). The distinction between isolated PLD and ADPKD relies on the number of renal cysts, age at presentation and family history (Table 4). In adults, younger than 30 years with a positive family history, the diagnosis of ADPKD is established by radiologic evidence of at least two unilateral or bilateral cysts. At least two cysts in each kidney are necessary for the diagnosis of patients between the age of 30 to 59 years, and at least four cysts in each kidney for patients 60 years or older[56]. It is worth noting that at least one third of patients with isolated PCLD may also have a few kidney cysts[15, 56, 57]. It has been proposed that sporadic cases of PCLD should be diagnosed when a patient has more than 15 to 20 cysts and no previous family history[1, 18] while four cysts suffice in the presence of a positive familial history[1, 18].

**INFECTED** **CYSTS**

Hepatic cysts may become infected, and cause life-threatening sepsis[58, 59]. Often, infected hepatic cysts are responsible for recurrent episodes of fever without any other signs or symptoms. In these circumstances, the diagnosis can be quite difficult as the accuracy of imaging tests remain low due to the altered anatomy of the liver parenchyma[60]. A promising investigation technique for suspected infected hepatic cysts is In-111 WBC scan[61]. Several other tracers such as 99mTc-diphosphonates, 67Gacitrate, and 111In- or 99mTc-labeled leukocytes have also been used[62]. Although labeled leukocyte imaging is theoretically the test of choice for detecting most infections, it is labor intensive, not always available and involves direct handling of potentially infected blood products. Therefore, considerable effort has been devoted to search for alternatives to this procedure such as the use of 67Gallium scintigraphy and 18F-FDG-positron emission tomography (PET). In recent years, PET has become the most commonly used diagnostic test for the detection of infected renal and hepatic cysts[60, 62, 63]. However, the accuracy of this technique is still under investigation. The literature on the treatment of infected cysts in PLD patients is very scarce and based only on a few case reports. Most of patients will need parenteral broad spectrum antibiotic therapy with percutanous drainage of the content of the cyst if their symptoms persists

**CLASSIFICATION**
Several clinical classifications have been proposed to grade the severity of PLD.

**GIGOT’S CLASSIFICATION**

 Gigot’s classification relies on imaging findings and was designed to identify the best candidates for fenestration of symptomatic cysts[38] (Figure 3): Type I: presence of less than 10 large hepatic cysts measuring more than 10 cm in maximum diameter. Type II: diffuse involvement of liver parenchyma by multiple cysts with remaining large areas of non-cystic liver parenchyma. Type III: presence of diffuse involvement of liver parenchyma by small and medium-sized liver cysts with only a few areas of normal liver parenchyma.

**QUIAN’S CLASSIFICATION**

Qian’s classification has been used in the context of familial screening and relies on the number of cysts and the presence of symptomatic hepatomegaly[18]: (1) Grade 0 - 0 cysts; (2) Grade 1 - 1 to 10 cysts; (3) Grade 2 - 11 to 20 cysts; (4) Grade 3 - more than 20 cysts; and (5) Grade 4 - more than 20 cysts and symptomatic hepatomegaly.

**SCHNELLDORFER’S CLASSIFICATION**

Schnelldorfer’s classification aims at differentiating patients who could benefit from resection or transplantation as summarized in Table 5[64].

**TREATMENT**
Most patients with PLD are asymptomatic and do not require any intervention[6]. However, symptomatic PCLD patients might require treatment when they experience severe dysfunction of organs around the liver due to the increased hepatic volume or when one or more cysts get torted, infected or develop intra-cystic hemorrhages (Table 6).

**AVOIDANCE OF EXPOSURE TO ESTROGENS**

Observational and experimental studies have shown that PLD may worsen under the influence of estrogen during pregnancy or when patients are prescribed estrogen replacement therapy[1, 27, 31]. Estrogen can increase both the number of liver cysts and their volume, therefore, hormonal therapy should be stopped in most symptomatic patients when appropriate[27].

**NON-SURGICAL TREATMENTS**

Medical management may be valuable in symptomatic patients with Gigot’s Type II/III.

**SOMATOSTATIN ANALOGUES**

Somatostatin analogues are inhibitors of cAMP and they reduce the secretion of fluid and the proliferation of many cell types, including cholangiocytes[65-69]. They also suppress the expression of insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), and other cystogenic growth factors[70]. In addition, somatostatin analogues inhibit the downstream signaling of these receptors[70]. Two randomized controlled trials have recently demonstrated that after 6 to 12 months, treatment with lanreotide, a long-acting somatostatin analogue, was associated with a significant reduction of liver volume in patients with PLD compared with placebo[28, 29]. However, the average hepatic volume reduction was only 3% to 5%. The severity of abdominal symptoms was also not significantly improved[28]. Currently, somatostatin analogues are indicated only for a selected group of patients with symptomatic PLD in whom the risks for surgical intervention are not justified, or in whom the surgical intervention is technically challenging.

**M-TOR INHIBITORS**

M-TOR inhibitors have immunosuppressive and antiproliferative effects[71]. Sirolimus and Everolimus were studied in Phase-II prospective randomised control trials. None of the two drugs showed substantial therapeutic effects both in humans[72-74] and in animal models[75]. Clinical prospective data o the effect of m-TOR inhibitors are currently not available, and this class of medications should not be recommended outside clinical trials.

**INTERVENTIONAL RADIOLOGY: ARTERIAL EMBOLIZATION**

Trans-catheter arterial embolization has been used since the early 2000s[76]. Hepatic artery branches supplying the hepatic segments replaced by the cysts are targeted by using microcoils or polyvinyl alcohol particles measuring 150 to 250 μm in diameter[76,77]. For patients with advanced PLD and multilobal disease, trans-catheter arterial embolization can be technically demanding. The largest series of patients treated with this modality included 30 patients who had a significant reduction of the volume of their cysts (6.667 ± 2.978 cm3 down to 4.625 ± 2.299 cm3), whereas the volume of the unaffected hepatic parenchyma increased[76]. After several months, patients reported improvement of their symptoms and no major complications except for occasional post-embolization syndrome[76, 77].

 **PERCUTANEOUS SCLEROTHERAPY**

This technique requires radiologically guided percutaneous aspiration of the content of the cysts followed by the injection of a sclerosing agent that inhibit the reaccumulation of fluid by damaging the epithelial lining the cystS[78, 79]. Symptomatic patients with one to five large dominant cysts (Gigot’s type I) are suitable for percutaneous sclerotherapy. Most commonly, cysts with a diameter larger than 5 cm are candidates for this treatment[10]. Puncturing of the cyst can be done with a 5 or 7 French catheter[80] and sclerosing agents commonly used include ethanol, ethanolamine oleate, minocycline and tetracycline. Although a single session is often sufficient, some patients require more than one[81]. Aspiration with sclerotherapy has an excellent safety profile, although severe abdominal pain can be caused by peritoneal irritation due to spillage of the sclerosing agent[10]. The majority of patients who undergo percutaneous sclerotherapy has improved symptoms in the immediate period following the procedure[10], but only 20% will have partial, or full regression of their disease[10].

**SURGERY**
Patient and treatment selection remain a clinical challenge. There is no consensus on selection criteria for surgery, the optimal timing, and technique. Current surgical options include fenestration, partial liver resection and OLT. Fenestration and partial liver resection are options for Gigot’s type I and II patients. For Gigot’s type III disease, fenestration and partial liver resection are often ineffective, and OLT should be considered as it is the only curative treatment. In general, several factors have to be considered before any surgical intervention is recommended: (1) The degree of cystic burden; (2) The distribution of the cysts; and (3) The proximity of the cysts to the main biliary ducts and portal and hepatic vein branches.

**SURGICAL PEARLS**

In Gigot’s type I or II, symptoms might not be related to the size of the entire liver but to the size of one or two large cysts. These patients can be treated similarlty to those with simple cysts. Some hepatic segments such as V and VI are frequently spared and, therefore, surgical resection can be performed if the spared liver parenchyma is thought to be sufficient. Frequently, the right hepatic veins are compressed by cysts causing the formation of collateral circulation between the right and the middle hepatic veins that can be responsible for intraoperative bleeding during the parenchymal transaction.

**FENESTRATION**
Fenestration is a surgical technique that combines aspiration and surgical unroofing of the cyst. It has the advantage that multiple cysts can be treated in one session[48, 82]. Fenestration is effective in symptomatic patients with Gigot’s Type I and II disease[83]. Patients with superficial and a limited number of large cysts are the best candidates for this procedure[48]. Fenestration may be achieved by laparotomy or laparoscopy[48]. Patients with the majority of their cysts located in the right posterior segments (VI, VII), or at the dome of the liver (segment VIII) may be better candidates for open fenestration because these cysts are difficult to be visualized and fenestrated by laparoscopic approach[48]. Published series describing open and laparoscopic fenestration are summarized in Table 7. Immediate symptom relief is achieved in 92% of the patients, whereas up to 25% experience recurrence of the cysts or symptoms[10]. Complication rate after fenestration is in the range of 23% while mortality is about 2%[10]. Complications include ascites, pleural effusion, hemorrhage and bile leakage[84]. Factors that predict failure of fenestration are previous abdominal procedures, deep-seated cysts, incomplete unroofing, cysts in segments VII-VIII, and the presence of diffuse PCLD[10].

**HEPATIC RESECTION WITH FENESTRATION**

Hepatic resection is usually reserved for highly symptomatic patients who are incapacitated by their disease due to the massive expansion of their livers (Gigot’s Type II and III)[38]. In these circumstances fenestration alone is rarely successful because the liver parenchyma is rigid and it does not collapse[10]. Symptom relief is achieved in 86% of cases although cyst recurrence is expected in one third of patients[10]. Overall, most of the patients have an improvement in their quality of life and functional status[36]. The morbidity rate associated with this procedure can be up to 50% and includes ascites, pleural effusions, biliary leakage, and hemorrhage[10]. One of the reasons for these complications is the fact that there is a significant distortion of the intra-hepatic vasculature and biliary tree which makes these procedures technically very challenging. Mortality rate is around 3%[10]. As subsequent adhesions may complicate future OLT, this surgical treatment is usually preserved for patients with massive hepatomegaly for which OLT is not an option[85, 86]. Published series describing hepatic resection with/without fenestration for symptomatic PCLD are summarized in Table 8.

**LIVER TRANSPLANTATION**

OLT is the only curative treatment for patients with severe PLD[87]. It is indicated in those patients with disabling symptoms that lead to decreased performance status and quality of life[10]. Patients with PLD usually have normal liver function and the current organ allocation system based on the Model for End-Stage Liver Disease (MELD) is often unable to assist this group of patients. For these patients, MELD exception criteria are needed[88, 89]. Because of the shortness of available grafts, the need for life-long immunosuppression and the perioperative risks, OLT is indicated only for symptomatic patients with Gigot’s Type II and III disease[12, 48, 90]. For patients undergoing OLT for PLD, perioperative morbidity is 40%-50%, whereas overall mortality is 10%-17%[10]. In 3% of patients, retransplantation is required[10] and combined renal and liver transplantation are necessary in 42% of patients[91, 92]. Expected survival at 1- and 5-year are 93% and 92% for patients undergoing OLT alone while for patients who undergo combined liver and kidney transplant are 86% and 80% respectively[10]. Published series reporting the outcomes of OLT for symptomatic PLD are summarized in Table 9.

**HEPATIC RESECTION VERSUS LIVER TRANSPLANTATION**

The clinical decision between performing a hepatic resection with or without cyst fenestration and referring the patient for OLT can be extremely difficult (Table 10). Hepatic resection with cyst fenestration implies leaving residual hepatic cysts that will eventually progress. However, hepatic resection is associated with a lower risk of perioperative morbidity and mortality. OLT provides the only option for the cure of these patients but requires lifelong immunosuppression and has higher perioperative risks. Both resection and OLT are technically demanding, and peri-operative care can be complex. The risks and the benefits of each of the possible treatment options have to be carefully evaluated and put in the contest of the clinical presentation and condition of each patient. Referral to a tertiary center with an experienced team of surgeons, hepatologists, and nephrologists is strongly recommended.

**CONCLUSION**
For patients with PLD, patients’ selection, timing and choice of treatments can be very challenging even for experienced physicians. For symptomatic patients, treatment strategies should be based on the degree and progression of their symptoms and the severity of other medical conditions. Symptomatic patients with large cysts or limited hepatic involvement might benefit from fenestration or sclerotherapy. Hepatic resection with or without fenestration should be favored in patients with diffuse involvement of the liver but with sufficient spared parenchyma. Finally, in the patient with diffuse disease, OLT is a valid option and should be pursued as primary therapy prior to the development of debilitating disease such as malnutrition and liver dysfunction that can significantly increase the risks of perioperative adverse events.

**REFERENCES**

1 **Hoevenaren IA**, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, Everson GT. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. *Liver Int* 2008; **28**: 264-270 [PMID: 17927714 DOI: 10.1111/j.1478-3231.2007.01595.x]

2 **Bristowe F**. Cystic disease of the liver associated with similar disease of the kidneys. . Trans Pathol Soc Lond 1856, **7**: 229-234

3 **Moschcowitz E.** Non-parasitic cysts (congenital) of the liver, with a study of aberrant bile ducts. The American Journal of the Medical Sciences 1906, **131**: 674–699 doi: 10.1097/00000441-190604000-00011

4 **FELDMAN M**. Polycystic disease of the liver. *Am J Gastroenterol* 1958; **29**: 83-86 [PMID: 13497992]

5 **Tahvanainen P**, Tahvanainen E, Reijonen H, Halme L, Kääriäinen H, Höckerstedt K. Polycystic liver disease is genetically heterogeneous: clinical and linkage studies in eight Finnish families. *J Hepatol* 2003; **38**: 39-43 [PMID: 12480558 DOI: 10.1016/S0168-8278(02)00348-3]

6 **Torres VE**. Treatment of polycystic liver disease: one size does not fit all. *Am J Kidney Dis* 2007; **49**: 725-728 [PMID: 17533013 DOI: 10.1053/j.ajkd.2007.04.009]

7 **Arnold HL**, Harrison SA. New advances in evaluation and management of patients with polycystic liver disease. *Am J Gastroenterol* 2005; **100**: 2569-2582 [PMID: 16279915 DOI: 10.1111/j.1572-0241.2005.00263.x]

8 **Vauthey JN**, Maddern GJ, Blumgart LH. Adult polycystic disease of the liver. *Br J Surg* 1991; **78**: 524-527 [PMID: 2059797 DOI: 10.1002/bjs.1800780505]

9 **Grünfeld JP**, Albouze G, Jungers P, Landais P, Dana A, Droz D, Moynot A, Lafforgue B, Boursztyn E, Franco D. Liver changes and complications in adult polycystic kidney disease. *Adv Nephrol Necker Hosp* 1985; **14**: 1-20 [PMID: 2983516]

10 **Drenth JP**, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. *Hepatology* 2010; **52**: 2223-2230 [PMID: 21105111 DOI: 10.1002/hep.24036]

11 **Temmerman F**, Missiaen L, Bammens B, Laleman W, Cassiman D, Verslype C, van Pelt J, Nevens F. Systematic review: the pathophysiology and management of polycystic liver disease. *Aliment Pharmacol Ther* 2011; **34**: 702-713 [PMID: 21790682 DOI: 10.1111/j.1365-2036.2011.04783.x]

12 **Qian Q**. Isolated polycystic liver disease. *Adv Chronic Kidney Dis* 2010; **17**: 181-189 [PMID: 20219621 DOI: 10.1053/j.ackd.2009.12.005]

13 **D'Agata ID**, Jonas MM, Perez-Atayde AR, Guay-Woodford LM. Combined cystic disease of the liver and kidney. *Semin Liver Dis* 1994; **14**: 215-228 [PMID: 7939783 DOI: 10.1055/s-2007-1007313]

14 **Davila S**, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, Cai Y, Kamath PS, King BF, Azurmendi PJ, Tahvanainen P, Kääriäinen H, Höckerstedt K, Devuyst O, Pirson Y, Martin RS, Lifton RP, Tahvanainen E, Torres VE, Somlo S. Mutations in SEC63 cause autosomal dominant polycystic liver disease. *Nat Genet* 2004; **36**: 575-577 [PMID: 15133510 DOI: 10.1038/ng1357]

15 **Van Keimpema L**, De Koning DB, Van Hoek B, Van Den Berg AP, Van Oijen MG, De Man RA, Nevens F, Drenth JP. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. *Liver Int* 2011; **31**: 92-98 [PMID: 20408955 DOI: 10.1111/j.1478-3231.2010.02247.x]

16 **Desmet VJ**. Ludwig symposium on biliary disorders--part I. Pathogenesis of ductal plate abnormalities. *Mayo Clin Proc* 1998; **73**: 80-89 [PMID: 9443684 DOI: 10.1016/S0025-6196(11)63624-0]

17 **Ramos A**, Torres VE, Holley KE, Offord KP, Rakela J, Ludwig J. The liver in autosomal dominant polycystic kidney disease. Implications for pathogenesis. *Arch Pathol Lab Med* 1990; **114**: 180-184 [PMID: 2302034]

18 **Qian Q**, Li A, King BF, Kamath PS, Lager DJ, Huston J, Shub C, Davila S, Somlo S, Torres VE. Clinical profile of autosomal dominant polycystic liver disease. *Hepatology* 2003; **37**: 164-171 [PMID: 12500201 DOI: 10.1053/jhep.2003.50006]

19 **Lazaridis KN**, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. *Gastroenterology* 2004; **127**: 1565-1577 [PMID: 15521023 DOI: 10.1053/j.gastro.2004.08.006]

20 **Everson GT**, Emmett M, Brown WR, Redmond P, Thickman D. Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in vivo secretion in response to secretin. *Hepatology* 1990; **11**: 557-565 [PMID: 1970324 DOI: 10.1002/hep.1840110406]

21 **Perrone RD**, Grubman SA, Rogers LC, Lee DW, Moy E, Murray SL, Torres VE, Jefferson DM. Continuous epithelial cell lines from ADPKD liver cysts exhibit characteristics of intrahepatic biliary epithelium. *Am J Physiol* 1995; **269**: G335-G345 [PMID: 7573443]

22 **Nichols MT**, Gidey E, Matzakos T, Dahl R, Stiegmann G, Shah RJ, Grantham JJ, Fitz JG, Doctor RB. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. *Hepatology* 2004; **40**: 836-846 [PMID: 15382115]

23 **Wheatley DN**. Primary cilia in normal and pathological tissues. *Pathobiology* 1995; **63**: 222-238 [PMID: 8866794 DOI: 10.1159/000163955]

24 **Ong AC**, Wheatley DN. Polycystic kidney disease--the ciliary connection. *Lancet* 2003; **361**: 774-776 [PMID: 12620752 DOI: 10.1016/S0140-6736(03)12662-1]

25 **Davenport JR**, Yoder BK. An incredible decade for the primary cilium: a look at a once-forgotten organelle. *Am J Physiol Renal Physiol* 2005; **289**: F1159-F1169 [PMID: 16275743 DOI: 10.1152/ajprenal.00118.2005]

26 **Harris RA**, Gray DW, Britton BJ, Toogood GJ, Morris PJ. Hepatic cystic disease in an adult polycystic kidney disease transplant population. *Aust N Z J Surg* 1996; **66**: 166-168 [PMID: 8639135 DOI: 10.1111/j.1445-2197.1996.tb01148.x]

27 **Sherstha R**, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, Everson GT. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. *Hepatology* 1997; **26**: 1282-1286 [PMID: 9362373]

28 **van Keimpema L**, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. *Gastroenterology* 2009; **137**: 1661-8.e1-2 [PMID: 19646443]

29 **Hogan MC**, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR, Rossetti S, Harris PC, LaRusso NF, Torres VE. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. *J Am Soc Nephrol* 2010; **21**: 1052-1061 [PMID: 20431041 DOI: 10.1681/ASN.2009121291]

30 **Caroli A**, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. *Clin J Am Soc Nephrol* 2010; **5**: 783-789 [PMID: 20185596 DOI: 10.2215/CJN.05380709]

31 **Alvaro D**, Mancino MG, Onori P, Franchitto A, Alpini G, Francis H, Glaser S, Gaudio E. Estrogens and the pathophysiology of the biliary tree. *World J Gastroenterol* 2006; **12**: 3537-3545 [PMID: 16773710]

32 **Everson GT**, Scherzinger A, Berger-Leff N, Reichen J, Lezotte D, Manco-Johnson M, Gabow P. Polycystic liver disease: quantitation of parenchymal and cyst volumes from computed tomography images and clinical correlates of hepatic cysts. *Hepatology* ; **8**: 1627-1634 [PMID: 3192176 DOI: 10.1002/hep.1840080626]

33 **Dmitrewski J**, Olliff S, Buckels JA. Obstructive jaundice associated with polycystic liver disease. *HPB Surg* 1996; **10**: 117-120 [PMID: 9184868 DOI: 10.1155/1996/83547]

34 **Abascal J**, Moya M, Martin F. Infection of hepatic cysts in polycystic disease. *World J Surg* 1984; **8**: 424-425 [PMID: 6380124 DOI: 10.1007/BF01655097]

35 **van Erpecum KJ**, Janssens AR, Terpstra JL, Tjon A Tham RT. Highly symptomatic adult polycystic disease of the liver. A report of fifteen cases. *J Hepatol* 1987; **5**: 109-117 [PMID: 3655307 DOI: 10.1016/S0168-8278(87)80068-5]

36 **Que F**, Nagorney DM, Gross JB, Torres VE. Liver resection and cyst fenestration in the treatment of severe polycystic liver disease. *Gastroenterology* 1995; **108**: 487-494 [PMID: 7835591 DOI: 10.1016/0016-5085(95)90078-0]

37 **Kabbej M**, Sauvanet A, Chauveau D, Farges O, Belghiti J. Laparoscopic fenestration in polycystic liver disease. *Br J Surg* 1996; **83**: 1697-1701 [PMID: 9038542 DOI: 10.1002/bjs.1800831211]

38 **Gigot JF**, Jadoul P, Que F, Van Beers BE, Etienne J, Horsmans Y, Collard A, Geubel A, Pringot J, Kestens PJ. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? *Ann Surg* 1997; **225**: 286-294 [PMID: 9060585 DOI: 10.1097/00000658-199703000-00008]

39 **Waanders E**, van Keimpema L, Brouwer JT, van Oijen MG, Aerts R, Sweep FC, Nevens F, Drenth JP. Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. *Liver Int* 2009; **29**: 1389-1395 [PMID: 19515221 DOI: 10.1111/j.1478-3231.2009.02055.x]

40 **Deschênes M**, Michel RP, Alpert E, Barkun JS, Metrakos P, Tchervenkov J. Elevation of CA-125 level is due to abdominal distension in liver transplantation candidates. *Transplantation* 2001; **72**: 1519-1522 [PMID: 11707739 DOI: 10.1097/00007890-200111150-00008]

41 **Iwase K**, Takenaka H, Oshima S, Yagura A, Nishimura Y, Yoshidome K, Tanaka T. Determination of tumor marker levels in cystic fluid of benign liver cysts. *Dig Dis Sci* 1992; **37**: 1648-1654 [PMID: 1385056 DOI: 10.1007/BF01299853]

42 **McCormick SE**, Sjogren MH, Goodman ZD. A 22-year-old man with a liver mass and markedly elevated serum alpha fetoprotein. *Semin Liver Dis* 1994; **14**: 395-403 [PMID: 7531871 DOI: 10.1055/s-2007-1007330]

43 **Schievink WI**, Spetzler RF. Screening for intracranial aneurysms in patients with isolated polycystic liver disease. *J Neurosurg* 1998; **89**: 719-721 [PMID: 9817407 DOI: 10.3171/jns.1998.89.5.0719]

44 **Ong AC**. Screening for intracranial aneurysms in ADPKD. *BMJ* 2009; **339**: b3763 [PMID: 19770180 DOI: 10.1136/bmj.b3763]

45 **Lumiaho A**, Ikäheimo R, Miettinen R, Niemitukia L, Laitinen T, Rantala A, Lampainen E, Laakso M, Hartikainen J. Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. *Am J Kidney Dis* 2001; **38**: 1208-1216 [PMID: 11728952 DOI: 10.1053/ajkd.2001.29216]

46 **Xu HW**, Yu SQ, Mei CL, Li MH. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. *Stroke* 2011; **42**: 204-206 [PMID: 21164130 DOI: 10.1161/STROKEAHA.110.578740]

47 **Ecder T**, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. *Nat Rev Nephrol* 2009; **5**: 221-228 [PMID: 19322187 DOI: 10.1038/nrneph.2009.13]

48 **Russell RT**, Pinson CW. Surgical management of polycystic liver disease. *World J Gastroenterol* 2007; **13**: 5052-5059 [PMID: 17876869]

49 **Torra R**, Nicolau C, Badenas C, Navarro S, Pérez L, Estivill X, Darnell A. Ultrasonographic study of pancreatic cysts in autosomal dominant polycystic kidney disease. *Clin Nephrol* 1997; **47**: 19-22 [PMID: 9021236]

50 **Blyth H**, Ockenden BG. Polycystic disease of kidney and liver presenting in childhood. *J Med Genet* 1971; **8**: 257-284 [PMID: 5097134 DOI: 10.1136/jmg.8.3.257]

51 **Milutinovic J**, Schabel SI, Ainsworth SK. Autosomal dominant polycystic kidney disease with liver and pancreatic involvement in early childhood. *Am J Kidney Dis* 1989; **13**: 340-344 [PMID: 2705452]

52 **Levine E**, Cook LT, Grantham JJ. Liver cysts in autosomal-dominant polycystic kidney disease: clinical and computed tomographic study. *AJR Am J Roentgenol* 1985; **145**: 229-233 [PMID: 3875218 DOI: 10.2214/ajr.145.2.229]

53 **Nicolau C**, Torra R, Bianchi L, Vilana R, Gilabert R, Darnell A, Brú C. Abdominal sonographic study of autosomal dominant polycystic kidney disease. *J Clin Ultrasound* ; **28**: 277-282 [PMID: 10867665]

54 **Bae KT**, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. *Clin J Am Soc Nephrol* 2006; **1**: 64-69 [PMID: 17699192 DOI: 10.2215/CJN.00080605]

55 **Vachha B**, Sun MR, Siewert B, Eisenberg RL. Cystic lesions of the liver. *AJR Am J Roentgenol* 2011; **196**: W355-W366 [PMID: 21427297 DOI: 10.2214/AJR.10.5292]

56 **Ravine D**, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. *Lancet* 1994; **343**: 824-827 [PMID: 7908078 DOI: 10.1016/S0140-6736(94)92026-5]

57 **Carrim ZI**, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. *Clin Radiol* 2003; **58**: 626-629 [PMID: 12887956 DOI: 10.1016/S0009-9260(03)00165-X]

58 **Chauveau D**, Fakhouri F, Grünfeld JP. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. *J Am Soc Nephrol* 2000; **11**: 1767-1775 [PMID: 10966503]

59 **Torres VE**, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. *Lancet* 2007; **369**: 1287-1301 [PMID: 17434405 DOI: 10.1016/S0140-6736(07)60601-1]

60 **Migali G**, Annet L, Lonneux M, Devuyst O. Renal cyst infection in autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant* 2008; **23**: 404-405 [PMID: 17913735 DOI: 10.1093/ndt/gfm665]

61 **Lahiri SA**, Halff GA, Speeg KV, Esterl RM. In-111 WBC scan localizes infected hepatic cysts and confirms their complete resection in adult polycystic kidney disease. *Clin Nucl Med* 1998; **23**: 33-34 [PMID: 9442963 DOI: 10.1097/00003072-199801000-00010]

62 **Soussan M**, Sberro R, Wartski M, Fakhouri F, Pecking AP, Alberini JL. Diagnosis and localization of renal cyst infection by 18F-fluorodeoxyglucose PET/CT in polycystic kidney disease. *Ann Nucl Med* 2008; **22**: 529-531 [PMID: 18670861 DOI: 10.1007/s12149-008-0150-3]

63 **Bleeker-Rovers CP**, de Sévaux RG, van Hamersvelt HW, Corstens FH, Oyen WJ. Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 2003; **41**: E18-E21 [PMID: 12776306 DOI: 10.1016/S0272-6386(03)00368-8]

64 **Schnelldorfer T**, Torres VE, Zakaria S, Rosen CB, Nagorney DM. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. *Ann Surg* 2009; **250**: 112-118 [PMID: 19561475 DOI: 10.1097/SLA.0b013e3181ad83dc]

65 **Alvaro D**, Gigliozzi A, Attili AF. Regulation and deregulation of cholangiocyte proliferation. *J Hepatol* 2000; **33**: 333-340 [PMID: 10952254 DOI: 10.1016/S0168-8278(00)80377-3]

66 **Møller LN**, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. *Biochim Biophys Acta* 2003; **1616**: 1-84 [PMID: 14507421 DOI: 10.1016/S0005-2736(03)00235-9]

67 **Heisler S**, Srikant CB. Somatostatin-14 and somatostatin-28 pretreatment down-regulate somatostatin-14 receptors and have biphasic effects on forskolin-stimulated cyclic adenosine, 3',5'-monophosphate synthesis and adrenocorticotropin secretion in mouse anterior pituitary tumor cells. *Endocrinology* 1985; **117**: 217-225 [PMID: 2861077 DOI: 10.1210/endo-117-1-217]

68 **Jakobs KH**, Gehring U, Gaugler B, Pfeuffer T, Schultz G. Occurrence of an inhibitory guanine nucleotide-binding regulatory component of the adenylate cyclase system in cyc- variants of S49 lymphoma cells. *Eur J Biochem* 1983; **130**: 605-611 [PMID: 6297910 DOI: 10.1111/j.1432-1033.1983.tb07192.x]

69 **Tan CK**, Podila PV, Taylor JE, Nagorney DM, Wiseman GA, Gores GJ, LaRusso NF. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. *Gastroenterology* 1995; **108**: 1908-1916 [PMID: 7768398 DOI: 10.1016/0016-5085(95)90157-4]

70 **Pyronnet S**, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. *Mol Cell Endocrinol* 2008; **286**: 230-237 [PMID: 18359151 DOI: 10.1016/j.mce.2008.02.002]

71 **Walz G**. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? *Nephrol Dial Transplant* 2006; **21**: 1752-1757 [PMID: 16705023 DOI: 10.1093/ndt/gfl246]

72 **Serra AL**, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. *N Engl J Med* 2010; **363**: 820-829 [PMID: 20581391 DOI: 10.1056/NEJMoa0907419]

73 **Walz G**, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU. Everolimus in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2010; **363**: 830-840 [PMID: 20581392 DOI: 10.1056/NEJMoa1003491]

74 **Watnick T**, Germino GG. mTOR inhibitors in polycystic kidney disease. *N Engl J Med* 2010; **363**: 879-881 [PMID: 20581393 DOI: 10.1056/NEJMe1006925]

75 **Renken C**, Fischer DC, Kundt G, Gretz N, Haffner D. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. *Nephrol Dial Transplant* 2011; **26**: 92-100 [PMID: 20615907 DOI: 10.1093/ndt/gfq384]

76 **Takei R**, Ubara Y, Hoshino J, Higa Y, Suwabe T, Sogawa Y, Nomura K, Nakanishi S, Sawa N, Katori H, Takemoto F, Hara S, Takaichi K. Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 2007; **49**: 744-752 [PMID: 17533017 DOI: 10.1053/j.ajkd.2007.03.018]

77 **Park HC**, Kim CW, Ro H, Moon JY, Oh KH, Kim Y, Lee JS, Yin YH, Jae HJ, Chung JW, Ahn C, Hwang YH. Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients. *J Korean Med Sci* 2009; **24**: 57-61 [PMID: 19270814 DOI: 10.3346/jkms.2009.24.1.57]

78 **Saini S**, Mueller PR, Ferrucci JT, Simeone JF, Wittenberg J, Butch RJ. Percutaneous aspiration of hepatic cysts does not provide definitive therapy. *AJR Am J Roentgenol* 1983; **141**: 559-560 [PMID: 6603770 DOI: 10.2214/ajr.141.3.559]

79 **Bean WJ**, Rodan BA. Hepatic cysts: treatment with alcohol. *AJR Am J Roentgenol* 1985; **144**: 237-241 [PMID: 3880981 DOI: 10.2214/ajr.144.2.237]

80 **van Keimpema L**, de Koning DB, Strijk SP, Drenth JP. Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts. *Dig Dis Sci* 2008; **53**: 2251-2257 [PMID: 18299984 DOI: 10.1007/s10620-007-0121-x]

81 **Kairaluoma MI**, Leinonen A, Ståhlberg M, Päivänsalo M, Kiviniemi H, Siniluoto T. Percutaneous aspiration and alcohol sclerotherapy for symptomatic hepatic cysts. An alternative to surgical intervention. *Ann Surg* 1989; **210**: 208-215 [PMID: 2667475 DOI: 10.1097/00000658-198908000-00012]

82 **van Keimpema L**, Ruurda JP, Ernst MF, van Geffen HJ, Drenth JP. Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. *J Gastrointest Surg* 2008; **12**: 477-482 [PMID: 17957434 DOI: 10.1007/s11605-007-0376-8]

83 Surgical management of cystic lesions in the liver. *ANZ J Surg* 2012 [PMID: 22537174 DOI: 10.1111/j.1445-2197.2012.06096.x]

84 **van Keimpema L**, Drenth JP. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. *Ann Surg* 2011; **253**: 419; author reply 420 [PMID: 21173690 DOI: 10.1002/bjs.1800710331]

85 **Armitage NC**, Blumgart LH. Partial resection and fenestration in the treatment of polycystic liver disease. *Br J Surg* 1984; **71**: 242-244 [PMID: 6697135]

86 **Schindl MJ**, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. *Gut* 2005; **54**: 289-296 [PMID: 15647196 DOI: 10.1136/gut.2004.046524]

87 **Everson GT**, Taylor MR, Doctor RB. Polycystic disease of the liver. *Hepatology* 2004; **40**: 774-782 [PMID: 15382167]

88 **Freeman RB**, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, Klintmalm G, Blazek J, Hunter R, Punch J. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. *Liver Transpl* 2006; **12**: S128-S136 [PMID: 17123284 DOI: 10.1002/lt.20979]

89 **Arrazola L**, Moonka D, Gish RG, Everson GT. Model for end-stage liver disease (MELD) exception for polycystic liver disease. *Liver Transpl* 2006; **12**: S110-S111 [PMID: 17123287 DOI: 10.1002/lt.20974]

90 **Kirchner GI**, Rifai K, Cantz T, Nashan B, Terkamp C, Becker T, Strassburg C, Barg-Hock H, Wagner S, Lück R, Klempnauer J, Manns MP. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. *Liver Transpl* 2006; **12**: 1268-1277 [PMID: 16741930 DOI: 10.1002/lt.20780]

91 **Rasmussen A**, Davies HF, Jamieson NV, Evans DB, Calne RY. Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival. *Transplantation* 1995; **59**: 919-921 [PMID: 7701595]

92 **Pirenne J**, Aerts R, Yoong K, Gunson B, Koshiba T, Fourneau I, Mayer D, Buckels J, Mirza D, Roskams T, Elias E, Nevens F, Fevery J, McMaster P. Liver transplantation for polycystic liver disease. *Liver Transpl* 2001; **7**: 238-245 [PMID: 11244166 DOI: 10.1053/jlts.2001.22178]

93 **Liska V**, Treska V, Mírka H, Skalický T, Sutnar A, Ferda J. [Treatment strategy in non-parasitic benign cysts of the liver]. *Rozhl Chir* 2008; **87**: 512-516 [PMID: 19110943]

94 **Bai XL**, Liang TB, Yu J, Wang WL, Shen Y, Zhang M, Zheng SS. Long-term results of laparoscopic fenestration for patients with congenital liver cysts. *Hepatobiliary Pancreat Dis Int* 2007; **6**: 600-603 [PMID: 18086625]

95 **Palanivelu C**, Rangarajan M, Senthilkumar R, Madankumar MV. Laparoscopic management of symptomatic multiple hepatic cysts: a combination of deroofing and radical excision. *JSLS* 2007; **11**: 466-469 [PMID: 18237512]

96 **Garcea G**, Pattenden CJ, Stephenson J, Dennison AR, Berry DP. Nine-year single-center experience with nonparastic liver cysts: diagnosis and management. *Dig Dis Sci* 2007; **52**: 185-191 [PMID: 17160469 DOI: 10.1007/s10620-006-9545-y]

97 **Szabó LS**, Takács I, Arkosy P, Sápy P, Szentkereszty Z. Laparoscopic treatment of nonparasitic hepatic cysts. *Surg Endosc* 2006; **20**: 595-597 [PMID: 16437277 DOI: 10.1007/s00464-005-0206-6]

98 **Neri V**, Ambrosi A, Fersini A, Valentino TP. Laparoscopic treatment of biliary hepatic cysts: short- and medium-term results. *HPB (Oxford)* 2006; **8**: 306-310 [PMID: 18333141 DOI: 10.1080/13651820500465766]

99 **Kornprat P**, Cerwenka H, Bacher H, El-Shabrawi A, Tillich M, Langner C, Mischinger HJ. Surgical therapy options in polycystic liver disease. *Wien Klin Wochenschr* 2005; **117**: 215-218 [PMID: 15875761 DOI: 10.1007/s00508-005-0309-z]

100 **Robinson TN**, Stiegmann GV, Everson GT. Laparoscopic palliation of polycystic liver disease. *Surg Endosc* 2005; **19**: 130-132 [PMID: 15531969 DOI: 10.1007/s00464-004-8813-1]

101 **Fiamingo P**, Tedeschi U, Veroux M, Cillo U, Brolese A, Da Rold A, Madia C, Zanus G, D'Amico DF. Laparoscopic treatment of simple hepatic cysts and polycystic liver disease. *Surg Endosc* 2003; **17**: 623-626 [PMID: 12574922 DOI: 10.1007/s00464-002-9088-z]

102 **Tocchi A**, Mazzoni G, Costa G, Cassini D, Bettelli E, Agostini N, Miccini M. Symptomatic nonparasitic hepatic cysts: options for and results of surgical management. *Arch Surg* 2002; **137**: 154-158 [PMID: 11822951 DOI: 10.1001/archsurg.137.2.154]

103 **Martin IJ**, McKinley AJ, Currie EJ, Holmes P, Garden OJ. Tailoring the management of nonparasitic liver cysts. *Ann Surg* 1998; **228**: 167-172 [PMID: 9712560 DOI: 10.1097/00000658-199808000-00004]

104 **Koperna T**, Vogl S, Satzinger U, Schulz F. Nonparasitic cysts of the liver: results and options of surgical treatment. *World J Surg* 1997; **21**: 850-84; discussion 850-84; [PMID: 9327677 DOI: 10.1007/s002689900316]

105 **Morino M**, Garrone C, Festa V, Miglietta C. [Laparoscopic treatment of non parasitic liver cysts]. *Ann Chir* 1996; **50**: 419-25; discussion 426-30 [PMID: 8991197]

106 **Farges O**, Bismuth H. Fenestration in the management of polycystic liver disease. *World J Surg* 1995; **19**: 25-30 [PMID: 7740806 DOI: 10.1007/BF00316975]

107 **Li TJ**, Zhang HB, Lu JH, Zhao J, Yang N, Yang GS. Treatment of polycystic liver disease with resection-fenestration and a new classification. *World J Gastroenterol* 2008; **14**: 5066-5072 [PMID: 18763291 DOI: 10.3748/wjg.14.5066]

108 **Gamblin TC**, Holloway SE, Heckman JT, Geller DA. Laparoscopic resection of benign hepatic cysts: a new standard. *J Am Coll Surg* 2008; **207**: 731-736 [PMID: 18954786 DOI: 10.1016/j.jamcollsurg.2008.07.009]

109 **Yang GS**, Li QG, Lu JH, Yang N, Zhang HB, Zhou XP. Combined hepatic resection with fenestration for highly symptomatic polycystic liver disease: A report on seven patients. *World J Gastroenterol* 2004; **10**: 2598-2601 [PMID: 15300916]

110 **Vons C**, Chauveau D, Martinod E, Smadja C, Capron F, Grunfeld JP, Franco D. [Liver resection in patients with polycystic liver disease]. *Gastroenterol Clin Biol* 1998; **22**: 50-54 [PMID: 9762166]

111 **Soravia C**, Mentha G, Giostra E, Morel P, Rohner A. Surgery for adult polycystic liver disease. *Surgery* 1995; **117**: 272-275 [PMID: 7878532 DOI: 10.1016/S0039-6060(05)80201-6]

112 **Henne-Bruns D**, Klomp HJ, Kremer B. Non-parasitic liver cysts and polycystic liver disease: results of surgical treatment. *Hepatogastroenterology* 1993; **40**: 1-5 [PMID: 8462920]

113 **Vauthey JN**, Maddern GJ, Kolbinger P, Baer HU, Blumgart LH. Clinical experience with adult polycystic liver disease. *Br J Surg* 1992; **79**: 562-565 [PMID: 1611453 DOI: 10.1002/bjs.1800790629]

114 **Sanchez H**, Gagner M, Rossi RL, Jenkins RL, Lewis WD, Munson JL, Braasch JW. Surgical management of nonparasitic cystic liver disease. *Am J Surg* 1991; **161**: 113-118; discussion 113-118; [PMID: 1987844 DOI: 10.1016/0002-9610(91)90370-S]

115 **Newman KD**, Torres VE, Rakela J, Nagorney DM. Treatment of highly symptomatic polycystic liver disease. Preliminary experience with a combined hepatic resection-fenestration procedure. *Ann Surg* 1990; **212**: 30-37 [PMID: 2363601 DOI: 10.1097/00000658-199007000-00005]

116 **Iwatsuki S**, Starzl TE. Personal experience with 411 hepatic resections. *Ann Surg* 1988; **208**: 421-434 [PMID: 3178330 DOI: 10.1097/00000658-198810000-00004]

117 **Taner B**, Willingham DL, Hewitt WR, Grewal HP, Nguyen JH, Hughes CB. Polycystic liver disease and liver transplantation: single-institution experience. *Transplant Proc* 2009; **41**: 3769-3771 [PMID: 19917384 DOI: 10.1016/j.transproceed.2009.05.043]

118 **Ueno T**, Barri YM, Netto GJ, Martin A, Onaca N, Sanchez EQ, Chinnakotla S, Randall HB, Dawson S, Levy MF, Goldstein RM, Klintmalm GB. Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome. *Transplantation* 2006; **82**: 501-507 [PMID: 16926594 DOI: 10.1097/01.tp.0000231712.75645.7a]

119 **Ueda M**, Egawa H, Oike F, Taira K, Uryuhara K, Fujimoto Y, Kozaki K, Tanaka K. Living-donor liver transplantation for polycystic liver disease. *Transplantation* 2004; **77**: 480-481 [PMID: 14966436 DOI: 10.1097/01.TP.0000110319.60723.31]

120 **Gustafsson BI**, Friman S, Mjornstedt L, Olausson M, Backman L. Liver transplantation for polycystic liver disease--indications and outcome. *Transplant Proc* 2003; **35**: 813-814 [PMID: 12644149 DOI: 10.1016/S0041-1345(03)00081-2]

121 **Swenson K**, Seu P, Kinkhabwala M, Maggard M, Martin P, Goss J, Busuttil R. Liver transplantation for adult polycystic liver disease. *Hepatology* 1998; **28**: 412-415 [PMID: 9696005 DOI: 10.1002/hep.510280218]

122 **Lang H**, von Woellwarth J, Oldhafer KJ, Behrend M, Schlitt HJ, Nashan B, Pichlmayr R. Liver transplantation in patients with polycystic liver disease. *Transplant Proc* 1997; **29**: 2832-2833 [PMID: 9365580 DOI: 10.1016/S0041-1345(97)00696-9]

123 **Washburn WK**, Johnson LB, Lewis WD, Jenkins RL. Liver transplantation for adult polycystic liver disease. *Liver Transpl Surg* 1996; **2**: 17-22 [PMID: 9346624 DOI: 10.1002/lt.500020105]

124 **Starzl TE**, Reyes J, Tzakis A, Mieles L, Todo S, Gordon R. Liver transplantation for polycystic liver disease. *Arch Surg* 1990; **125**: 575-577 [PMID: 2331212 DOI: 10.1001/archsurg.1990.01410170021003]

**P-Reviewers** Drenth JPH, Hori T, Llado L, Schemmer P  **S-Editor** Wen LL  **L-Editor**  **E-Editor**

**PCLD**

**Ductal-plate malformation**

**Abnormal primary cilia**

**Figure 1 Pathophysiology of polycystic liver disease.** PCLD: Polycystic liver disease.



**Type I**

**Type III**

**Type II**

A



B



C

**Figure 2 Gigot’s Classification for polycystic liver diseases.** A: Graphical representation; B:Abdominal magnetic resonance imaging of a patient affected by Gigot I cystic liver disease; C: Abdominal computerized tomography of a patient affected by Gigot II cystic liver disease.



**A**



**B**



**C**

**Figure 3 Gigot’s classification relies on imaging findings and was designed to identify the best candidates for fenestration of symptomatic cysts.** A: Intreaveneous contrast enhanced computerized tomography (CT) of a patient affected by polycystic liver and renal disease. The cysts appears hypoattenuating with smooth and regular walls; B: T2 magnetic resonance imaging of a patient with multiple hepatic cysts. The cystic fluid appears bright on T2 images; C: Abdominal CT of a patient affected by Gigot III cystic liver disease.

**Table 1 Comparative epidemiological and genetic mutation characteristics of autosomal dominant polycystic kidney disease associated polycystic liver disease and isolated polycystic liver disease**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | **ADPKD associated PCLD** | **Isolated PCLD** |
| Prevalence  | 0.2% | < 0.01% |
| Type of inheritance  | AD | AD |
| Gene mutated | PKD1; PKD2 | PRKCSH; SEC63 |
| Encoded product  | Polycystin-1; Polycystin-2 | Hepatocystin; Sec63 protein  |
| Chromosome locus | 216p13.3; 4q21 | 19p13.2; 6q21 |

AD: Autosomal dominant; ADPKD: Autosomal dominant polycystic kidney disease; PCLD: Polycystic liver disease.

**Table 2 Risk factors for liver-cyst growth in polycystic liver disease**

|  |
| --- |
| **Risk factors for liver-cyst growth in polycystic liver disease** |
| Advancing patient age  |
| Female gender  |
| Estrogen exposure: multiple pregnancies, OCP’s, estrogen replacement therapy  |
| Severity of renal dysfunction and renal cyst volume  |

OCP’s: Oral contraceptive pills.

**Table 3 Summary of the most frequent symptoms caused by polycystic liver disease**

|  |  |
| --- | --- |
| **Symptoms due to mass effect**  | **Symptoms due to complications of the cysts** |
| Abdominal distentionEarly satietyPostprandial fullnessGastro-oesophageal refluxMalnutritionDyspnoeaHepatic venous-outflow obstruction (Budd-Chiari Syndrome)Inferior vena cava syndromePortal-vein compressionBile-duct compression | InfectionTorsionRuptureHaemorrhage |

**Table 4 The ravine diagnostic criteria for autosomal dominant polycystic kidney disease**

|  |  |
| --- | --- |
| **Patient’s age (yr)** | **Number of cysts** |
| **Positive family history** | **Negative family history** |
| ≤ 30 | At least 2 cysts affecting 1 or both kidneys | At least 5 cysts |
| 31–59 | At least 2 cysts in each kidney | At least 5 cysts |
| ≥ 60 | At least 4 cysts in each kidney | At least 8 cysts |

**Table 5 Summary of Schnelldorfer’s classification that aims at differentiating patients who could benefit from resection or transplantation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Type A** | **Type B** | **Type C** | **Type D** |
| **Symptoms** | Absent or mild | Moderate or severe | Severe (or moderate) | Severe (or moderate) |
| **Cyst characteristics** | Any | Limited No. large cysts | Any | Any |
| **Areas of relative normal liver parenchyma** | Any | ≥ 2 sectors | ≥ 1 sector | < 1 sector |
| **Presence of portal vein or hepatic vein occlusion in the preserved hepatic sectors** | Any | Absent | Absent | Present |
| **Recommended therapy** | Observation or medical therapy | Cyst fenestration | Partial hepatectomy with possible fenestration of remnant cysts | Liver Transplantation |

**Table 6 Summary of treatment options for polycystic liver disease**

|  |  |
| --- | --- |
| **Treatment approach** | **Treatment type** |
| Nonsurgical | * Medical
1. Somatostatin analogues
2. mTOR inhibitors
* Interventional Radiology:
1. Arterial embolization
2. Percutaneous sclerotherapy
 |
| Surgical | * Fenestration
* Hepatic resection with fenestration
* Liver transplantation
 |

OCP’s: Oral contraceptive pills; ERT: Estrogen replacement therapy; mTOR: Mammalian target of rapamycin.

**Table 7 Summary of largest series published on the surgical techniques used for cystic fenestration of symptomatic polycystic liver disease**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author** | **Number of patients** | **Technique** | **Outcome** | **Complications** | **Follow-up (months)** |
| **Liska *et al***[93] | 7 | Lap fenestration plus open | — | No mortality | Mean 41 |
| **van Keimpema *et al*[**[**82**](#_ENREF_77)**]** | 12 | Lap fenestration | Reduction in liver volume by 12.5% | Bile leak, vena cava occlusion and sepsis | — |
| **Bai *et al*[**[**94**](#_ENREF_89)**]** | 10 | Lap fenestration | Symptom and cyst recurrence in 20% | 3 patients with minor complications.No mortality | Mean of 57 |
| **Palanivelu *et al*[**[**95**](#_ENREF_90)**]** | 4 | Lap fenestration | 100% cyst recurrence | — | — |
| **Garcea *et al*[**[**96**](#_ENREF_91)**]** | 6 | Lap/Open fenestration | 16.7% symptom recurrence, 33.3% cyst recurrence | 50% morbidity | 5–36 |
| **Szabó *et al*[**[**92**](#_ENREF_92)**]** | 4 | Lap fenestration | 100% symptom relief | 50% cyst recurrence | — |
| **Neri *et al*[**[**98**](#_ENREF_93)**]** | 3 | Lap fenestration | 100% symptom relief | 50% morbidity | — |
| **Kornprat *et al*[**[**99**](#_ENREF_94)**]** | 8 | Lap fenestration | 0% symptom recurrence | — | — |
| **Robinson *et al*[**[**100**](#_ENREF_95)**]** | 11 | Lap fenestration | 54.5% symptom recurrence | — | — |
| **Fiamingo *et al*[**[**101**](#_ENREF_96)**]** | 6 | Lap fenestration | 30% symptom recurrence | 50% morbidity | 1–64 |
| **Tocchi *et al*[**[**102**](#_ENREF_97)**]** | 18 | Lap / open fenestration | — | — | — |
| **Martin *et al*[**[**118**](#_ENREF_98)**]** | 13 | Open fenestration (*n* = 6); Lap (*n* = 13) | 71% symptom recurrence | 30% morbidity | 37 mean follow-up |
| **Koperna *et al*[**[**104**](#_ENREF_99)**]** | 39 | Open fenestration (*n* =34); Lap in 5 | 21% symptom recurrence | — | 75 mean follow-up |
| **Kabbej *et al*[**[**37**](#_ENREF_37)**]** | 13 | Lap fenestration | 72% symptom recurrence | 54% morbidity | Mean follow-up 26 |
| **Morino *et al*[**[**105**](#_ENREF_100)**]** | 7 | Lap fenestration | 40% symptom recurrence | 44% morbidity rate | — |
| **Gigot *et al*[**[**38**](#_ENREF_38)**]** | 10 | Open fenestration | 11% symptom recurrence | 60% morbidity | 73 mean follow-up |
| **Farges *et al*[**[**106**](#_ENREF_101)**]**  | 13 | Open fenestration | 23% symptom recurrence | 69% morbidity | 84 follow-up |
| **van Erpecum *et al*[**[**35**](#_ENREF_35)**]** | 15 | Open fenestration | 0% symptom recurrence | One mortality | Mean of 48 |

**Legend**: Lap = Laparoscopic

**Table 8 Summary of largest series published on the surgical techniques used for cystic fenestration and resection of symptomatic polycystic liver disease**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author** | **Number** | **Technique** | **Outcome** | **Complications** | **Follow-up (mo)** |
| **Schnelldorfer *et al*[64]** | 124 | Fenestration and resection | 93% symptom relief, 72.6% recurrent cyst formation | 72.6% morbidity, 3.2% mortality | Mean of 48 |
| **Li *et al*[**[**107**](#_ENREF_102)**]** | 21 | Fenestration and resection | 14.3% cyst recurrence | 76.2% cyst morbidity, 0% mortality | 10–155 |
| **Gamblin *et al*[**[**108**](#_ENREF_103)**]** | 51 | Fenestration and resection | 3.9% symptom recurrence | 17.6% morbidity, no mortality | 1–49 |
| **Kornprat *et al*[**[**99**](#_ENREF_94)**]** | 9 | Fenestration and resection | 100% symptom relief, 11% recurrence | 33.35 morbidity | 24–98 |
| **Yang *et al*[**[**109**](#_ENREF_104)**]** | 7 | Fenestration and resection | 100% symptom recurrence | 100% morbidity, no mortality | Mean of 20 |
| **Vons *et al*[**[**110**](#_ENREF_105)**]** | 12 | Resection | 17% symptom recurrence | 8% mortality, 83% morbidity | Mean of 34 |
| **Koperna *et al***[[104](#_ENREF_99)] | 5 | Fenestration and resection | 0% symptom recurrence | — | — |
| **Soravia *et al*[**[**111**](#_ENREF_106)**]** | 10 | Fenestration and resection | 33% symptom recurrence | 10% mortality, 20% morbidity | Mean of 69 |
| **Que *et al*[**[**36**](#_ENREF_36)**]** | 31 | Fenestration and resection | 3% symptom recurrence | 3% mortality, 58% morbidity | Mean of 28 |
| **Henne-Bruns *et al*[**[**112**](#_ENREF_107)**]** | 8 | Fenestration and resection | 50% symptom recurrence | No mortality, 38% morbidity | Mean of 15 |
| **Vauthey *et al*[**[**113**](#_ENREF_108)**]** | 5 | Fenestration and resection | 0% symptom recurrence | 0% mortality, 100% morbidity | Mean of 14 |
| **Sanchez *et al*[**[**114**](#_ENREF_109)**]** | 9 | Resection | 100% symptom relief, 100% recurrence | 0% mortality | Mean of 35 |
| **Newman *et al*[**[**115**](#_ENREF_110)**]** | 9 | Fenestration and resection | 88.9% symptom relief, 0% recurrence | 11.1% mortality, 55.6% morbidity | 2–44 |
| **Iwatsuki *et al*[**[**116**](#_ENREF_111)**]** | 9 | Resection | 44.4% symptom relief, 44.4% recurrence | 0% mortality, 33.3% morbidity | 12–180 |

**Table 9 Summary of largest series published on the outcomes of patients undergoing liver transplantation for symptomatic polycystic liver disease**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Number of Patients** | **Previous surgery** | **Combined liver and kidney transplantation**  | **Morbidity** | **Mortality** | **Follow-up****(months)** | **Re-transplantation** |
| **Taner *et al*[**[**117**](#_ENREF_112)**]** | 13 | **—** | 54% | 85% | 31% | **—** | 0% |
| **Ueno *et al*[**[**118**](#_ENREF_113)**]** | 14 | **—** | 36% | 64% | 21% | **—** | 0% |
| **Ueda *et al*[**[**119**](#_ENREF_114)**]** | 3 | **—** | 0 | 33% | 0% | Mean of 32 | 0% |
| **Gustafsson *et al*[**[**120**](#_ENREF_115)**]** | 7 | 57% | 43% | 57% | 43% | Mean of 4 | 0% |
| **Pirenne *et al*[**[**92**](#_ENREF_87)**]** | 16 | 25% | 6% | 38% | 13% | Range 18–120 | 0% |
| **Swenson *et al*[**[**121**](#_ENREF_116)**]** | 9 | 44% | 33% | 44% | 11% | Mean of 26 | 11% |
| **Lang *et al*[**[**122**](#_ENREF_117)**]** | 17 | 35% | 47% | 47% | 29% | Mean of 12 | 12% |
| **Washburn [**[**123**](#_ENREF_118)**]** | 5 | 90% | 20% | 0% | 20% | Mean of 38 | 0% |
| **Starzl *et al*[**[**124**](#_ENREF_119)**]** | 4 | 0% | 25% | 0% | 50% | Mean of 38 | 0% |

**Table 10 Suggested management strategies based on Gigot’s classification**

|  |  |
| --- | --- |
| **Gigot’s I** | **Gigot’s II - III** |
| Percutaneous sclerotherapy | Hepatic resection with fenestration if feasible |
| Fenestration | Liver transplantatio |